Expert Interview
Discussing the Alzheimer's landscape with focus on Biogen's Lecanemab in light of the recent FDA approval
Ticker(s): EISAI, BIIBInstitution: Mercy Medical Center
- Manages 30 patients with MG,and 200 patients with Alzheimer's Disease
- Has prescribed Vyvgart, and is very familiar with the recent data for Lecanemab
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
